Healthcare ❯ Pharmaceutical Industry ❯ Obesity Treatments ❯ Drug Development

Market Competition

Metsera Backs Pfizer’s $10 Billion Deal, Citing Regulatory Risks in Novo Bid

FTC concerns over Novo’s two-step structure made Pfizer’s revised offer the board’s preferred path.

Novo Nordisk Raises Metsera Bid to $10 Billion, Outpacing Pfizer’s $8.1 Billion Counter